Welcome to our dedicated page for QT Imaging Holdings news (Ticker: QTI), a resource for investors and traders seeking the latest updates and insights on QT Imaging Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QT Imaging Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QT Imaging Holdings's position in the market.
QT Imaging (Nasdaq: QTI) released a mid‑year 2026 CEO letter highlighting strong commercial, financial, regulatory and clinical progress for its Breast Acoustic CT platform. In the first half of 2026, the company generated $14.0 million in revenue, up 116% year over year, and shipped 28 scanners, double the prior‑year period. QT Imaging reported no revenue in 2023, followed by $4.9 million in 2024 and $18.9 million in 2025, and reiterated ~$39 million 2026 revenue guidance.
The company completed a $10 million underwritten public offering, extended its senior secured term loan maturity to March 31, 2029, and held about $14.2 million in cash and restricted cash as of August 7, 2026. QT Imaging returned to the Nasdaq Capital Market, was added to the Russell Microcap Index, and reported over 12,000 women imaged. It obtained two new FDA clearances, completed its first routine FDA inspection with zero Form 483 observations, secured regulatory authorizations in Saudi Arabia, UAE and Israel, expanded U.S. and international distribution partnerships, advanced multiple clinical studies, demonstrated <1% variability in quantitative biomarkers, and received an AMA Category III CPT code released on July 1, 2026 for 3D quantitative transmission volumetric ultrasound tomography of the breast.
QT Imaging (Nasdaq: QTI) reported strong growth for the quarter ended June 30, 2026, with second-quarter revenue of $7.4 million, up 103% from $3.7 million a year earlier, driven by shipment of 15 Breast Acoustic CT scanners. First-half 2026 revenue rose 116% to $14.0 million on 28 scanners shipped.
The company completed a $10.0 million underwritten public offering, extended its senior secured term loan maturity to March 31, 2029, and reaffirmed 2026 revenue guidance of approximately $39 million. QT Imaging reported a second-quarter gross margin of 41%, operating loss of $1.9 million, and net loss of $11.1 million (including an $8.3 million non-cash loss on debt extinguishment). Cash and restricted cash totaled $11.0 million at June 30, 2026 and $14.2 million as of August 7, 2026.
QT Imaging (Nasdaq: QTI) will report its second quarter 2026 financial results for the period ended June 30, 2026 after market close on Wednesday, August 12, 2026, and will host a conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
According to QT Imaging, participants are encouraged to pre-register online, but U.S. callers can also join by dialing 866-777-2509, and international participants can dial 412-317-5413. A live and archived webcast of the call will be accessible via a provided link and through the IR Calendar section of the QT Imaging website.
QT Imaging (Nasdaq: QTI) advanced its direct U.S. commercial strategy for the Breast Acoustic CT Scanner by appointing breast imaging industry veterans Jason Dyer as Vice President Regional Sales East and Dave Reinhart as Vice President Regional Sales West. Both joined in July 2026 and report to Chief Commercial Officer Satrajit Misra.
According to QT Imaging, these hires support a shift from a primarily distributor-led model toward an integrated direct commercial organization while maintaining its existing U.S. distribution relationship with NXC Imaging, a Canon Medical Systems USA subsidiary. The expanded commercial team will target leading medical centers and integrated delivery networks, support evidence generation, physician education, quantitative imaging biomarker development, potential therapy-monitoring applications (subject to validation and regulatory clearances), and growth of recurring software and analytics revenue, including future AI-enabled Software-as-a-Service offerings.
QT Imaging (Nasdaq: QTI) appointed Julia Albright, Ph.D., as Chief Science Officer effective July 27, 2026. She brings more than 25 years of experience across medical imaging, digital health, oncology, cloud technologies, and healthcare AI.
As CSO, Dr. Albright will lead QT Imaging’s scientific strategy, collaborating with R&D, engineering, clinical, and product teams. Her focus will include quantitative breast imaging, AI-powered image analysis, clinical evidence generation, and development of the company’s next generation, radiation-free breast imaging technologies.
QT Imaging Holdings (NASDAQ: QTI) reported the results of its Annual Meeting of stockholders held on July 28, 2026. Stockholders approved the election of Professor Zeev Weiner and Bryan Timm as Class II directors through the 2029 Annual Meeting, the appointment of BPM LLP as independent registered public accounting firm for fiscal 2026, and an amendment to the 2024 Equity Incentive Plan to increase authorized shares. According to the company, detailed voting results will be filed on Form 8-K with the SEC.
QT Imaging (Nasdaq: QTI) received regulatory registration from the Israeli Ministry of Health for its Breast Acoustic CT™ Scanner, authorizing commercialization in Israel through February 2, 2028. The registration is based on existing U.S. FDA clearance and applicable Israeli regulatory requirements.
The radiation-free, compression-free 3D breast imaging system uses low-energy sound waves and provides quantitative imaging biomarkers as an adjunctive device for women aged 18 and older. The registration also supports QT Imaging’s collaboration with Rambam Health Care Campus, including a planned clinical study in women with hereditary risk for breast cancer.
QT Imaging (Nasdaq: QTI) completed its first routine FDA inspection with zero Form 483 observations, indicating no cited conditions that may constitute violations of applicable regulations.
The FDA reviewed QT Imaging’s Quality Management System and related operational processes, provided positive feedback on QMS organization and responsiveness, and the company views this as an important operational milestone supporting global commercialization and manufacturing scale-up.
QT Imaging (Nasdaq: QTI) announced that CEO Dr. Raluca Dinu presented the Shiftmaker Award to tennis champion and breast cancer survivor Martina Navratilova during Wimbledon week in London and joined high-profile panels on women’s health, breast health, early detection, and personalized care.
The events, hosted by The Shift, highlight QT Imaging’s commitment to advancing breast health with innovative imaging technologies that provide quantitative information and support more comfortable, patient-centered care.
QT Imaging (Nasdaq: QTI) reported multi-site data supporting strong reproducibility of its Breast Acoustic CT scanner’s quantitative biomarkers. Speed of Sound (SoS) measurements showed less than 1% variability within and across scanners, while volumetric metrics had about 5% variability for Total Breast Volume and 12% for FGV/TBV.
The study, conducted at two clinical sites with five patients per site scanned five times each, suggests this reproducibility can support longitudinal breast imaging and quantitative, data-driven breast health assessment.